Avenue Therapeutics
preclinical in studies demonstrate efficacy in multiple epilepsy models | Avenue Therapeutics
Company
Deck Type
IPO
Sector
Industry
Deck date
October 2022
Slide
15 of 30
Related slides by other companies
BioNTech
Results
August 2022
nucleoside modified encoding variable antibody formats for in translation gene medicine | BioNTech
Oscar Health
Investor Conference
January 2024
our results demonstrate the model is working | Oscar Health
Alkermes
Investor Day
March 2021
tumor targeted split advancing toward preclinical proof of concept and cell line development engineer tumor targeted subunits fused to proprietary tumor targeting antibody demonstrate that tumor targeted subunits are retained in tumors with expected kinetics demonstrate that sequentially administered subunits combine to form functional and drive dose dependent production in humanized mice complete humanization of tumor targeting antibodies ongoing characterize lead candidates and preclinical proof of concept studies planned initiate cell line development | Alkermes
Boundless Bio
IPO
March 2024
demonstrated proof of concept in multiple additional addicted models cest | Boundless Bio
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io